Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Clinical trial NCT05531786 · RECRUITING
Trial details
- NCT number
- NCT05531786
- Sponsor
- National Cancer Institute (NCI)
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-06
- Primary completion
- 2027-07-22
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.